Whole exome sequencing of patients having comorbidities associated with type 2 diabetes.
Not Applicable
- Conditions
- Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
- Registration Number
- CTRI/2020/01/022821
- Lead Sponsor
- Zifo RnD Solutions
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Case and control group will be confirmed based on Blood Fasting Glucose, Hb1AC, UACR, Serum Ceratinine and eGFR
Exclusion Criteria
No history of Type 1 diabetes
No nephropathy unrelated to diabetic nephropathy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Identification of biomarkers to study disease progression / pathophysiology <br/ ><br> <br/ ><br>Timepoint: 3 to 4 years down the line. <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1) Person specific tailored effective, safe medicine and dose (pharmacogenomics) <br/ ><br>2) Biomarker based early diagnosis (preventive medicine)Timepoint: 3 to 4 years down the line